top of page
tiga_newbanner.jpg

Unleashing the Tumor Killing Power of Neutrophils with Engineered IgA

A Differentiated Approach

Pioneering first-in-class, engineered IgA as neutrophil engagers to fight cancer. 

Our Leadership

We are a seasoned group of drug developers, backed by excellent investors with an accomplished scientific advisory board.  

Our Investors

web-bgv-gray.png
web-boehr-gray.png
web-nfv-gray.png
web-gbaf-gray.png
web-emerson-gray.png
web-alex-gray.png
web-civvent-gray.png
bottom of page